January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

If you're interested in broad exposure to the Healthcare - Broad segment of the equity market, look no further than the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund ...

Real-time index price for Dow Jones Industrials Average (DOWI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly And Co. (LLY) reported earnings for its fourth quarter that increased from last year and beat the Street estimates. The ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of non-incretin products, which grew sales 20% in the fourth quarter, should “help ...

Q4 2024 Management View CEO David Ricks highlighted a 45% revenue growth in Q4, with significant contributions from Mounjaro and Zepbound. He emphasized ongoing expansion in manufacturing to meet ...